Preston Wendell Wells Sells 165 Shares of Stryker (NYSE:SYK) Stock

Stryker Corporation (NYSE:SYK) CFO Preston Wendell Wells sold 165 shares of the business’s stock in a transaction dated Thursday, November 20th. The shares were sold at an average price of $365.88, for a total value of $60,370.20. Following the completion of the transaction, the chief financial officer directly owned 6,694 shares of the company’s stock, valued at approximately $2,449,200.72. The trade was a 2.41% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Stryker Stock Down 1.0%

Shares of SYK traded down $3.77 on Thursday, hitting $360.46. The company’s stock had a trading volume of 1,381,441 shares, compared to its average volume of 1,448,508. The company has a quick ratio of 1.06, a current ratio of 1.78 and a debt-to-equity ratio of 0.70. The firm has a market capitalization of $137.85 billion, a price-to-earnings ratio of 47.74, a P/E/G ratio of 2.66 and a beta of 0.94. The firm’s fifty day moving average price is $370.25 and its 200-day moving average price is $380.91. Stryker Corporation has a fifty-two week low of $329.16 and a fifty-two week high of $406.19.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Thursday, October 30th. The medical technology company reported $3.19 earnings per share for the quarter, beating analysts’ consensus estimates of $3.13 by $0.06. The firm had revenue of $6.06 billion for the quarter, compared to analyst estimates of $6.04 billion. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The business’s revenue was up 10.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.87 earnings per share. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. On average, equities research analysts expect that Stryker Corporation will post 13.47 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Vanguard Group Inc. grew its holdings in Stryker by 0.8% during the third quarter. Vanguard Group Inc. now owns 33,773,399 shares of the medical technology company’s stock worth $12,485,012,000 after purchasing an additional 272,828 shares during the period. State Street Corp lifted its position in shares of Stryker by 1.0% in the second quarter. State Street Corp now owns 14,956,732 shares of the medical technology company’s stock valued at $5,929,765,000 after buying an additional 150,204 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its stake in shares of Stryker by 9.2% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 12,131,218 shares of the medical technology company’s stock worth $4,515,847,000 after acquiring an additional 1,021,496 shares during the period. Geode Capital Management LLC grew its stake in Stryker by 1.1% in the 2nd quarter. Geode Capital Management LLC now owns 7,393,611 shares of the medical technology company’s stock valued at $2,910,445,000 after buying an additional 79,654 shares during the last quarter. Finally, Alliancebernstein L.P. increased its stake in shares of Stryker by 13.3% during the third quarter. Alliancebernstein L.P. now owns 6,338,050 shares of the medical technology company’s stock worth $2,342,987,000 after purchasing an additional 741,542 shares during the period. Institutional investors own 77.09% of the company’s stock.

Analysts Set New Price Targets

SYK has been the subject of a number of research reports. Sanford C. Bernstein reiterated an “outperform” rating on shares of Stryker in a report on Monday, November 3rd. Wall Street Zen upgraded Stryker from a “hold” rating to a “buy” rating in a report on Saturday, October 18th. Weiss Ratings restated a “hold (c+)” rating on shares of Stryker in a research note on Wednesday. Truist Financial raised their price target on shares of Stryker from $392.00 to $400.00 and gave the stock a “hold” rating in a research note on Friday, November 14th. Finally, Rothschild & Co Redburn began coverage on shares of Stryker in a report on Thursday, September 18th. They issued a “neutral” rating and a $420.00 price objective on the stock. Thirteen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat, Stryker currently has a consensus rating of “Moderate Buy” and an average target price of $434.37.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.